Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-226 · 1 trial · 1 indication
Transfusion independence is defined as the absence of any red blood cells (RBC) transfusions in a period of at least 8 weeks after the first dose of the study treatment through week 24.
| Arm | Type | Description |
|---|---|---|
| TAK-226 | EXPERIMENTAL | Participants will receive the study drug, TAK-226, administered subcutaneously every four weeks (Q4W) for approximately one year during Treatment Period. |
| Name | Type | Description |
|---|---|---|
| TAK-226 | DRUG | TAK-226 subcutaneous injection |
Inclusion Criteria: 1. Participants or their legally authorized representative must be willing and able to sign the ICF and to adhere to the protocol requirements. 2. Japanese adult male or female participant \>=18 years of age at the time of signing informed consent. 3. Diagnosis of MDS with or wi...
Top 20 of 34 competitors
TAK-226 is an investigational small molecule being studied for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS). It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
TAK-226 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company listed on the stock exchange under the ticker symbol TAK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
TAK-226 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating anemia in patients with lower-risk myelodysplastic syndromes.
TAK-226 is being evaluated in a Phase 2 clinical trial with the identifier NCT07319845. This study is titled 'A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes' and is currently recruiting participants in Japan. The trial is an uncontrolled, open-label study with an enrollment target of 42 patients.
No, TAK-226 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of anemia in patients with lower-risk myelodysplastic syndromes. The drug has not yet completed clinical trials or received regulatory approval from the FDA or other health authorities.